Expert consensus on the clinical application of long-acting cabotegravir and rilpivirine
- VernacularTitle:卡替拉韦联合利匹韦林长效抗逆转录病毒注射方案临床应用专家指导建议
- Author:
Lijun SUN
1
;
Hongxia WEI
;
Haibo DING
;
Ping MA
;
Hui WANG
;
Lijing WANG
;
Chunmei WANG
;
Min WANG
;
Qian WANG
;
Hai LONG
;
Jinchuan SHI
;
Wei LYU
;
Biao ZHU
;
Jun LIU
;
An LIU
;
Lianguo RUAN
;
Zaicun LI
;
Linghua LI
;
Huiqin LI
;
Shenghua HE
;
Meiyin ZOU
;
Yuxia SONG
;
Renfang ZHANG
;
Jian ZHANG
;
Xinping YANG
;
Yahong CHEN
;
Yaokai CHEN
;
Hongxin ZHAO
;
Qingxia ZHAO
;
Zhongsi HONG
;
Feng QIAN
;
Guangyong XU
;
Huihuang HUANG
;
Wei CAO
;
Jianhua YU
;
Juan JIN
;
Lin CAI
;
Fujie ZHANG
Author Information
- Publication Type:Journal Article
- Keywords: Antiretroviral therapy; Long-acting; Injectable regimen; Cabotegravir; Rilpivirine
- From: Chinese Journal of Clinical Infectious Diseases 2024;17(6):431-439
- CountryChina
- Language:Chinese
- Abstract: The long-acting cabotegravir and rilpivirine injection regimen（CAB+RPV regimen）is the first approved long-acting antiretroviral therapy（ART）for HIV in China，administered once every two months. This regimen provides an innovative alternative to daily oral ART，benefiting virologically suppressed patients. Several large clinical-studies have shown that the CAB+RPV regimen achieves comparable virologic suppression and safety to daily oral regimens，while significantly enhancing patient satisfaction. Based on international and domestic HIV/AIDs guidelines and clinical evidence，this consensus offers expert recommendations on patient selection，clinical management，and key communication strategies for healthcare providers to support the effective use of this regimen，aiming to improve quality of life for people living with HIV and accumulate domestic clinical experience with this advanced treatment approach.
